Medicamen Biotech Ltd's Q3FY25 Quarter Results
- 12 Feb 2025
Result Summary
- Medicamen Biotech Ltd reported a 0.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 4.3%.
- Its expenses for the quarter were down by 3.9% QoQ and 6.0% YoY.
- The net profit increased 220.9% QoQ and increased 43.8% YoY.
- The earnings per share (EPS) of Medicamen Biotech Ltd stood at 2.3 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 45.28 | 45.03 | 47.33 | 0.6% | -4.3% |
Total Expenses | 41.41 | 43.08 | 44.06 | -3.9% | -6.0% |
Profit Before Tax | 3.88 | 1.96 | 3.27 | 98.0% | 18.7% |
Tax | 0.96 | 1.05 | 1.24 | -8.6% | -22.6% |
Profit After Tax | 2.92 | 0.91 | 2.03 | 220.9% | 43.8% |
Earnings Per Share | 2.30 | 0.70 | 1.60 | 228.6% | 43.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Medicamen Biotech Ltd is a pharmaceutical company primarily engaged in the production and marketing of pharmaceutical formulations. It operates in the healthcare industry, focusing on the manufacturing of tablets, capsules, orals, and topical preparations. The company has been known for its commitment to quality and adherence to international standards in its production processes. While specific recent major developments are not detailed in the provided data, Medicamen Biotech Ltd has historically been involved in expansions and collaborations to enhance its manufacturing capacities and market reach. The business environment of the pharmaceutical industry involves strict regulatory compliance, technological advancements, and a focus on research and development to innovate and introduce new products to the market.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Medicamen Biotech Ltd reported total income of ₹45.28 crores. This represents a modest quarter-over-quarter (QoQ) increase of 0.6% compared to ₹45.03 crores in Q2FY25. However, there was a year-over-year (YoY) decline of 4.3% from ₹47.33 crores in Q3FY24. The revenue figures suggest a relatively stable performance over the quarter, with a slight decrease when compared to the previous year, indicating fluctuations in the company's income generation over the annual cycle. The data does not provide insights into the specific revenue streams or product lines contributing to this income.
Profitability
Medicamen Biotech Ltd achieved a significant improvement in profitability in Q3FY25, with a profit before tax of ₹3.88 crores. This marks a substantial QoQ growth of 98% from ₹1.96 crores in Q2FY25, and an 18.7% YoY increase from ₹3.27 crores in Q3FY24. The tax expense for the quarter was ₹0.96 crores, a decrease both QoQ by 8.6% and YoY by 22.6%. Consequently, the profit after tax soared to ₹2.92 crores, reflecting an impressive QoQ growth of 220.9% from ₹0.91 crores and a 43.8% YoY increase from ₹2.03 crores. Earnings per share also increased correspondingly, reaching ₹2.30, which is a 228.6% QoQ increase and a 43.7% YoY increase. The improvement in profitability metrics highlights the company's enhanced cost management and operational efficiency during the quarter.
Operating Metrics
The operating metrics of Medicamen Biotech Ltd for Q3FY25 show a decline in total expenses to ₹41.41 crores, a reduction of 3.9% QoQ from ₹43.08 crores in Q2FY25 and a 6.0% YoY decrease from ₹44.06 crores in Q3FY24. This reduction in expenses underscores the company's efforts in optimizing operational costs. The significant changes observed in profit margins are directly tied to the reduced expense levels, which have positively impacted the overall profitability despite the slight decline in total income. The financial data provided does not include specific operating ratios such as the P/E ratio or current ratio, thus restricting further detailed analysis of operational performance metrics. Nonetheless, the reported figures suggest a focused approach towards enhancing operational efficiency and profitability.
